These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8918578)

  • 1. Increase of tuberculous infection in the organs of B cell-deficient mice.
    Vordermeier HM; Venkataprasad N; Harris DP; Ivanyi J
    Clin Exp Immunol; 1996 Nov; 106(2):312-6. PubMed ID: 8918578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.
    Cafaro A; Piccaro G; Altavilla G; Gigantino V; Matarese G; Olivieri E; Ferrantelli F; Ensoli B; Palma C
    BMC Infect Dis; 2016 Aug; 16(1):442. PubMed ID: 27549342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal revaccination with Bacillus Calmette-Guérin elicits improved, early protection against Mycobacterium tuberculosis in mice.
    Li W; Huang H; Hua W; Ben S; Liu H; Xu B; Xian Q; Tang Z; Shen H
    Vaccine; 2012 May; 30(21):3223-30. PubMed ID: 22342709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis.
    Williams A; Davies A; Marsh PD; Chambers MA; Hewinson RG
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S299-301. PubMed ID: 10875804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis.
    Elias D; Akuffo H; Pawlowski A; Haile M; Schön T; Britton S
    Vaccine; 2005 Feb; 23(11):1326-34. PubMed ID: 15661380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice.
    Zhang H; Peng P; Miao S; Zhao Y; Mao F; Wang L; Bai Y; Xu Z; Wei S; Shi C
    Scand J Immunol; 2010 Oct; 72(4):349-57. PubMed ID: 20883320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70.
    Dai FY; Wang JF; Gong XL; Bao L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective Vaccine Efficacy of the Complete Form of PPE39 Protein from Mycobacterium tuberculosis Beijing/K Strain in Mice.
    Kim A; Hur YG; Gu S; Cho SN
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis.
    Olsen AW; Brandt L; Agger EM; van Pinxteren LA; Andersen P
    Scand J Immunol; 2004 Sep; 60(3):273-7. PubMed ID: 15320884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Miycobacterium bovis bacille Calmette-Guérin induce equal protection.
    Mollenkopf HJ; Kursar M; Kaufmann SH
    J Infect Dis; 2004 Aug; 190(3):588-97. PubMed ID: 15243936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.
    Triccas JA; Shklovskaya E; Spratt J; Ryan AA; Palendira U; Fazekas de St Groth B; Britton WJ
    Infect Immun; 2007 Nov; 75(11):5368-75. PubMed ID: 17724075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.
    Zelmer A; Tanner R; Stylianou E; Damelang T; Morris S; Izzo A; Williams A; Sharpe S; Pepponi I; Walker B; Hokey DA; McShane H; Brennan M; Fletcher H
    BMC Infect Dis; 2016 Aug; 16():412. PubMed ID: 27519524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal bacille Calmette-Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology.
    Tree JA; Williams A; Clark S; Hall G; Marsh PD; Ivanyi J
    Clin Exp Immunol; 2004 Dec; 138(3):405-9. PubMed ID: 15544615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
    Brodin P; Majlessi L; Brosch R; Smith D; Bancroft G; Clark S; Williams A; Leclerc C; Cole ST
    J Infect Dis; 2004 Jul; 190(1):115-22. PubMed ID: 15195250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
    Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
    Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (DL-lactide-co-glycolide) microparticles as carrier vehicles.
    Dhiman N; Khuller GK
    FEMS Immunol Med Microbiol; 1998 May; 21(1):19-28. PubMed ID: 9657317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance.
    Ladel CH; Daugelat S; Kaufmann SH
    Eur J Immunol; 1995 Feb; 25(2):377-84. PubMed ID: 7875199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.
    Xu ZZ; Chen X; Hu T; Meng C; Wang XB; Rao Y; Zhang XM; Yin YL; Pan ZM; Jiao XA
    Front Cell Infect Microbiol; 2016; 6():3. PubMed ID: 26858942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.